Detalles de la búsqueda
1.
Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database.
Br J Cancer;
130(8): 1269-1278, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38402342
2.
Drug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: does ceasing therapy due to toxicity worsen outcomes in long term?
Int J Clin Pract;
70(4): 340-50, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26987888
3.
Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.
Br J Cancer;
112(12): 1888-94, 2015 Jun 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-25989278
4.
Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.
Ann Oncol;
26(1): 13-21, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25115304
5.
Interpreting the clinical utility of a pharmacogenomic marker based on observational association studies.
Pharmacogenomics J;
14(1): 1-5, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24018622
6.
Exploration of the perceptions, barriers and drivers of pharmacogenomics practice among hospital pharmacists in Adelaide, South Australia.
Pharmacogenomics J;
14(3): 235-40, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24018620
7.
Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis.
Pharmacogenomics J;
14(4): 350-5, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24394199
8.
The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis.
Pharmacogenomics J;
14(5): 424-31, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24709690
9.
Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancer.
ESMO Open;
7(3): 100475, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35490579
10.
Towards integrated ADME prediction: past, present and future directions for modelling metabolism by UDP-glucuronosyltransferases.
J Mol Graph Model;
22(6): 507-17, 2004 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-15182810
11.
Challenges and limitations in the interpretation of systematic reviews: making sense of clopidogrel and CYP2C19 pharmacogenetics.
Clin Pharmacol Ther;
94(3): 376-82, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23670120
12.
The importance of high-quality evidence of the long-term impact of nonfatal events used in randomized controlled trials: a case study of prasugrel.
Clin Pharmacol Ther;
90(1): 27-9, 2011 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-21691272
13.
Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data.
J Thromb Haemost;
8(8): 1678-84, 2010 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-20492467
14.
In silico insights: chemical and structural characteristics associated with uridine diphosphate-glucuronosyltransferase substrate selectivity.
Clin Exp Pharmacol Physiol;
30(11): 836-40, 2003 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-14678246
Resultados
1 -
14
de 14
1
Próxima >
>>